DALLAS, March 20, 2015 /PRNewswire/ --

RnRMarketResearch.com adds "Glomerulonephritis - Pipeline Review, H1 2015" report to its store. The report provides an overview of the Glomerulonephritis's therapeutic pipeline.

The report "Glomerulonephritis - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Glomerulonephritis. Glomerulonephritis disease that leads to serious kidney failure unless treated at the right time. It is caused by the inflammation of the filtering units of the kidney called glomeruli. There are different ways in which one can diagnose this disease but it is important for one to be aware of its symptoms and take precautions as early as possible. Researchers are still on finding the best drug for this disease as there are very few drugs that can be prescribed as a remedy for this disease. These drugs are so strong that it leads to weight gain, hyperglycemia, agitation, damaging the bones, get bruised easily, and weakening of the skin.

With a lot of studies being undertaken to come up with a drug that will aid a person without causing any side effects, one might be interested to go through the Global Markets Direct's- Glomerulonephritis - Pipeline Review, H1 2015 (http://www.rnrmarketresearch.com/glomerulonephritis-pipeline-review-h1-2015-market-report.html) that provides an all-inclusive report on the development of Glomerulonephritis treatment including a detailed analysis of drug target, mechanism of action (MoA), route of administration (RoA) and molecule type together with the latest updates. It includes a detailed anlysis of the key players of the market like- Adienne Pharma & Biotech, Alexion Pharmaceuticals, Inc. , Avexxin AS, Biogen Idec Inc. , ChemoCentryx, Inc. , FibroStatin SL, GlaxoSmithKline plc, Hansa Medical AB, Mallinckrodt plc, New Zealand Pharmaceuticals Limited, Pharmalink AB & Toray Industries, Inc. It also includes a detailed drug profiling of  some the important drugs like AVX-235, elimumab, budesonide, CCX-168, corticotropin, DEXM-74 Drug to Inhibit GPBP for Glomerulonephritis and Cancer, eculizumab, Endoglycosidase of Streptococcus pyogenes, Mubodina, Peptide to Inhibit ETA and ETB for Rapidly Progressive Glomerulonephritis, rituximab Small Molecule to Inhibit Vitamin K Epoxide Reductase for Glomerulonephritis. The information under this section covers product description, MoA and R&D Progress.

Order a Purchase copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=314358 . (This is a premium report priced at US$2000 for a single user License.)

The scope of the report ranges from global therapeutic landscape of Glomerulonephritis to the recent news and deals undertaken in the field of pipeline review. There is a detailed assessment of monotherapy and combination therapy pipeline projects along with a products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages. The person referring to the report will be able to devise his R&D development strategies as it includes significant competitor information, analysis and valuable insights. The report mentions the new entrants to the market and the emerging players. The report also helps in developing and designing in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Very vital information included in the report is a list of discontinued projects and shelved projects. The report has been compiled from the information extracted from annual reports/SEC filings, proprietary databases belonging to Global Markets Direct, Company/University portals and other third party sources.

Explore more reports on Renal Therapeutics Market Research at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics/kidney/kidneyrenal-therapeutics .

More reports on Renal Therapeutics Market:

End-Stage Kidney Disease (end-stage renal disease or ESRD) Global Clinical Trials Review, H1, 2015 

This report provides elemental information and data relating to the clinical trials on End-Stage Kidney Disease (end-stage renal disease or ESRD). It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. Companies discussed in this report include Amgen Inc., Novartis AG, F. Hoffmann-La Roche Ltd., AstraZeneca PLC, Pfizer Inc., Sanofi, Shire Plc, Merck & Co., Inc., Baxter International Inc., AbbVie Inc. Complete report available at http://www.rnrmarketresearch.com/end-stage-kidney-disease-end-stage-renal-disease-or-esrd-global-clinical-trials-review-h1-2015-market-report.html .

Nephropathy Global Clinical Trials Review, H1, 2015 

The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Nephropathy. Companies discussed in this report include Pfizer Inc., Novartis AG, Mallinckrodt plc, Rigel Pharmaceuticals, Inc., Kliniken der Stadt Koln gGmbH, AstraZeneca PLC, Astellas Pharma Inc., Anthera Pharmaceuticals‚ Inc., AbbVie Inc. Complete report available at http://www.rnrmarketresearch.com/nephropathy-global-clinical-trials-review-h1-2015-market-report.html .

Pyelonephritis - Pipeline Review, H1 2015 

This report provides comprehensive information on the therapeutic development for Pyelonephritis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. Companies discussed in this report include Achaogen Inc., AstraZeneca PLC, Merck & Co., Inc., MerLion Pharmaceuticals Pte Ltd, The Medicines Company. Complete report available at http://www.rnrmarketresearch.com/pyelonephritis-pipeline-review-h1-2015-market-report.html .

Renal Insufficiency - Pipeline Review, H1 2015 

This report provides comprehensive information on the therapeutic development for Renal Insufficiency. Companies Involved in Therapeutics Development are Boehringer Ingelheim GmbH, Elcelyx Therapeutics, Inc., Nippon Zoki Pharmaceutical Co., Ltd., Novartis AG, Shire Plc, The Medicines Company. Complete report available at http://www.rnrmarketresearch.com/renal-insufficiency-pipeline-review-h1-2015-market-report.html .

About Us:
RnRMarketResearch.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.

Contact:
Ritesh Tiwari
TX, Dallas North - Dominion Plaza,
17304, Preston Road,
Suite 800, Dallas 75252
Tel:  +1-888-391-5441
This e-mail address is being protected from spambots. You need JavaScript enabled to view it

SOURCE RnR Market Research

...